Table 2.

Selected grade 1/2 treatment-related adverse events commonly reported with vascular endothelial growth factor inhibitors and laboratory test change by dose (all treated subjects)

	180 mg	320 mg	600 mg	800 mg C	800 mg I	1000 mg	400 mg b.i.d.
AEa related to study drug	n = 3	n = 14	n = 3	n = 20	n = 11	n = 4	n = 13
Nausea	1 (33)	6 (43)	2 (67)	7 (35)	3 (27)	3 (75)	5 (38.5)
Diarrhea	2 (67)	2 (14)	0 (0)	8 (40)	3 (27)	0 (0)	2 (15)
Fatigue	1 (33)	4 (29)	1 (33)	4 (20)	9 (82)	1 (25)	6 (46)
Dizziness	0 (0)	5 (36)	2 (67)	4 (20)	5 (46)	1 (25)	3 (23)
Hypertension	0 (0)	2 (14)	2 (67)	4 (20)	5 (46)	2 (50)	2 (15)
Vomiting	0 (0)	6 (43)	0 (0)	6 (30)	1 (9)	0 (0)	6 (46)
Constipation	1 (33)	2 (14)	0 (0)	2 (10)	0 (0)	0 (0)	0 (0)
Abdominal pain	0 (0)	1 (7)	0 (0)	1 (5)	1 (9)	0 (0)	0 (0)
Dyspepsia	0 (0)	1 (7)	1 (33)	0 (0)	1 (9)	0 (0)	0 (0)
Stomatitis	0 (0)	0 (0)	0 (0)	1 (5)	1 (9)	1 (25)	0 (0)
Anorexia	2 (67)	4 (29)	3 (100)	6 (30)	3 (27)	3 (75)	7 (54)
Proteinuria	0 (0)	2 (14)	0 (0)	2 (10)	1 (9)	0 (0)	1 (8)
Laboratory testsb	n = 3	n = 14	n = 3	n = 20	n = 11	n = 4	n = 10–12
AST increased	0 (0)	0 (0)	1 (33)	2 (10)	0 (0)	2 (50)	1 (8)
ALT increased	0 (0)	1 (7)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Bilirubin increased	0 (0)	0 (0)	0 (0)	1 (5)	0 (0)	0 (0)	0 (0)
Hyponatremia	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

^aNational Cancer Institute–Common Terminology Criteria for AEs, v 3.

^bGrade increase from baseline.

AE, adverse event; C, continuous; I, intermittent; AST, aspartate aminotransferase; ALT, alanine aminotransferase.